Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a publicly traded U.S. biopharmaceutical company headquartered in Coral Gables, Florida. Its business is centered on identifying, developing, acquiring, and commercializing medicines for rare neurological and neuromuscular disorders, with an emphasis on conditions where treatment options are limited and patient populations are comparatively small. Rather than operating primarily as a broad-based research pharmaceutical company, Catalyst has developed a commercial-stage model built around specialty medicines, regulatory development, orphan-disease expertise, and patient-support infrastructure. The company was founded in 2002 and completed its initial public offering in 2006. During its earlier years, Catalyst concentrated substantially on therapies intended to address addiction. Its research portfolio later broadened, including a 2009 license from Northwestern University for a family of GABA inhibitors that included CPP-115. Catalyst discontinued that program and ended the associated license in 2018. The company’s strategic direction changed decisively in 2012, when it obtained North American rights from BioMarin for amifampridine phosphate, also known as 3,4-diaminopyridine phosphate or 3,4-DAPP, for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst submitted a new drug application for amifampridine in December 2015. The FDA declined to accept the application in February 2016 because it considered the submission incomplete and subsequently advised Catalyst that additional data were needed. Catalyst resubmitted the application in March 2018. The FDA approved the product, under the brand name Firdapse, for adults with LEMS on November 29, 2018, and expanded the approved population to include children six years of age and older on November 28, 2018, according to the cited reference material. Firdapse entered commercial distribution in January 2019. In May 2024, the FDA approved a supplemental application raising the maximum daily dose for adults and pediatric patients weighing more than 45 kilograms from 80 milligrams to 100 milligrams. Firdapse became the company’s principal product and established Catalyst as a specialist in rare neuromuscular disease commercialization. The company also operates patient-access services under the Catalyst Pathways name. These services have included financial-assistance support, insurance navigation, bridge medication, and patient-access liaison functions intended to help patients obtain specialty medicines. Catalyst expanded beyond LEMS through licensing and acquisition activity. In July 2023, it acquired North American rights to AGAMREE, an oral suspension containing vamorolone, from its previous rights holder. The FDA had approved AGAMREE in October 2023 for Duchenne muscular dystrophy in patients aged two years and older, and Catalyst commercially launched the product in March 2024. In January 2023, the company also acquired U.S. rights to FYCOMPA (perampanel), an epilepsy medicine with FDA-approved oral suspension and monotherapy uses. These transactions broadened Catalyst’s commercial portfolio while retaining its concentration on neurological disorders. Leadership changed at the end of 2023. Patrick J. McEnany retired as chief executive officer in October 2023 and continued as chairman, while Richard J. Daly became chief executive officer on January 1, 2024. Catalyst’s current positioning combines rare-disease commercialization, licensing and acquisition of established or late-stage assets, regulatory execution, and patient-support programs. Its major commercial focus is the United States, with portfolio expansion shaped by opportunities in neurological, neuromuscular, and other rare-disease markets.

Catalyst Pharmaceuticals was established in 2002 and became a public company through an initial public offering in 2006. Its initial research orientation was directed mainly toward treatments intended to prevent or reduce addiction. The company later moved toward rare neurological disease, a field in which small patient populations, limited therapeutic alternatives, orphan-drug incentives, and specialized regulatory requirements create a distinct commercial model. In 2009, Catalyst licensed worldwide rights from Northwestern University to a group of GABA-inhibitor compounds, including CPP-115. The program represented an earlier attempt to build a proprietary development pipeline. Catalyst ultimately terminated the CPP-115 license and discontinued development of the compound in 2018, as its business became more focused on commercially actionable rare-disease assets. The pivotal strategic step came in 2012. Catalyst licensed North American patents and related rights from BioMarin covering amifampridine phosphate for Lambert-Eaton myasthenic syndrome. LEMS is a rare autoimmune neuromuscular disorder involving impaired communication between nerves and muscles and is associated with limb weakness and other muscle symptoms. Amifampridine, also called 3,4-diaminopyridine or 3,4-DAP in related formulations, had been used in investigational and compassionate-use settings before U.S. regulatory approval. Catalyst assumed responsibility for advancing the U.S. development and regulatory program while a Phase III study was ongoing. The regulatory path was not immediate. Catalyst submitted a new drug application in December 2015, but the FDA refused to accept it in February 2016 because the submission was incomplete. In April of that year, the company was informed that additional data would be required. Catalyst resubmitted the application in March 2018. The FDA approved Firdapse for adults with LEMS on November 29, 2018; the cited material also identifies a November 28, 2018 approval covering children six years and older in addition to the earlier adult indication. Firdapse launched commercially in January 2019, becoming Catalyst's leading product and the foundation of its commercial-stage identity. The approval generated debate over orphan-drug exclusivity and the transition from free investigational access to a commercial product. In late 2015, neuromuscular physicians published an editorial expressing concern that approval could result in a substantial price increase and arguing that the phosphate formulation did not represent sufficient innovation to warrant exclusivity. Catalyst responded in 2016 that it had undertaken the clinical and nonclinical work required for approval and that the regulatory framework was intended to encourage development for diseases affecting small populations. In 2019, Senator Bernie Sanders sent a public letter questioning Firdapse pricing and its consequences for patients who had previously received amifampridine through compassionate use. The exclusivity issue later entered federal litigation. In January 2022, the Eleventh Circuit's decision in Catalyst Pharmaceuticals, Inc. v. Becerra upheld Catalyst's orphan-drug exclusivity and rejected the FDA position that had allowed approval of a competing product from Jacobus Pharmaceutical. The ruling reinforced the commercial protections surrounding Firdapse while also illustrating the regulatory and legal tensions associated with rare-disease medicines. Catalyst broadened its portfolio through additional rights acquisitions. In January 2023, it acquired U.S. rights to FYCOMPA (perampanel), an epilepsy medicine that had received prior FDA approvals for an oral suspension formulation and for monotherapy use. In July 2023, Catalyst acquired North American rights to AGAMREE (vamorolone), an oral suspension for Duchenne muscular dystrophy. AGAMREE received FDA approval in October 2023 and was launched by Catalyst in March 2024 for patients aged two and older. Vamorolone's clinical development included comparisons with prednisone and was positioned around maintaining muscle function while potentially reducing certain corticosteroid-associated effects. The company also developed Catalyst Pathways, a patient-support platform offering assistance such as insurance navigation, financial support, bridge medication, and patient-access liaison services. These programs support the practical distribution of specialty medicines to patients with rare conditions. In October 2023, long-serving chief executive Patrick J. McEnany retired from the CEO role and became chairman. Richard J. Daly took over as CEO on January 1, 2024. By that point, Catalyst had evolved from an early-stage company with an addiction-focused research emphasis into a public, commercial-stage rare-disease biopharmaceutical company with products in LEMS, Duchenne muscular dystrophy, and epilepsy. Its present strategy is based on combining internal regulatory and commercialization capabilities with licensing and acquisition of neurological medicines.

1. 2024AGAMREE launch and Firdapse dose expansion

   Catalyst launched AGAMREE in March, and the FDA approved a supplemental application increasing the maximum indicated Firdapse dose in May.

   Source
2. 2023FYCOMPA rights acquired

   Catalyst acquired U.S. rights to the epilepsy medicine FYCOMPA.

   Source
3. 2023AGAMREE rights acquired

   Catalyst acquired North American rights to AGAMREE, a vamorolone oral suspension for Duchenne muscular dystrophy.

   Source
4. 2022Orphan-exclusivity litigation decision

   The Eleventh Circuit upheld Catalyst's orphan-drug exclusivity for Firdapse in Catalyst Pharmaceuticals, Inc. v. Becerra.

   Source
5. 2019Firdapse commercial launch

   Catalyst launched Firdapse commercially in the United States.

   Source
6. 2018Firdapse receives FDA approval

   The FDA approved Firdapse for LEMS, establishing Catalyst's first major commercial product.

   Source
7. 2016FDA requests additional data

   The FDA did not accept the initial application and advised Catalyst that additional information was needed.

   Source
8. 2015Firdapse application submitted

   Catalyst submitted a new drug application for amifampridine phosphate.

   Source
9. 2012North American amifampridine rights acquired

   Catalyst licensed North American rights and related patents for amifampridine phosphate in LEMS from BioMarin.

   Source
10. 2009CPP-115 licensing agreement

    Catalyst licensed worldwide rights from Northwestern University to a family of GABA inhibitors that included CPP-115.

    Source
11. 2006Initial public offering

    Catalyst completed its initial public offering and became a publicly traded company.

    Source
12. 2002Company founded

    Catalyst Pharmaceuticals was founded in the United States.

    Source

A specialty biopharmaceutical company focused on commercializing and expanding access to therapies for rare neurological and neuromuscular diseases.

• FirdapseRare-disease neuromuscular medicine2019

  Firdapse is Catalyst's branded formulation of amifampridine phosphate, also known as 3,4-diaminopyridine phosphate. It is used to improve neuromuscular transmission in patients with Lambert-Eaton myasthenic syndrome, a rare disorder characterized by muscle weakness. The FDA approved it for adults in 2018 and for children six years of age and older. Catalyst launched it commercially in January 2019. A 2024 supplemental approval increased the maximum daily dose for adults and pediatric patients weighing more than 45 kilograms.

• AGAMREENeuromuscular disease medicine2024

  AGAMREE is an oral suspension containing vamorolone for Duchenne muscular dystrophy. The FDA approved it in October 2023 for patients aged two years and older. Catalyst acquired North American rights in July 2023 and launched the product commercially in March 2024. Clinical evidence cited in the reference material included a comparison with prednisone and indicated preservation of muscle function, with fewer reported effects in certain bone-health, growth, and behavioral categories.

• FYCOMPAEpilepsy medicine2023

  FYCOMPA is the brand name for perampanel, an epilepsy medicine. Catalyst acquired U.S. rights in January 2023. The product had received earlier FDA approvals for an oral suspension formulation and for use as monotherapy. Its addition expanded Catalyst's commercial presence in neurological disease beyond rare neuromuscular disorders.

• CPP-115Investigational neurological compound

  CPP-115 was an investigational GABA-inhibitor compound licensed by Catalyst from Northwestern University in 2009 as part of a broader compound family. Catalyst terminated the license and stopped the development program in 2018. It is therefore a former research program rather than a current commercial offering.

• Catalyst PathwaysPatient-support service

  Catalyst Pathways is a patient-access and support program associated with Catalyst's specialty medicines. Services described in the reference material include financial-assistance support, insurance navigation, bridge medication, and patient-access liaison assistance. The program is intended to address practical barriers that can affect patients seeking treatment for rare neurological conditions.

• 2022Catalyst Pathways patient-support program

  United States

  Catalyst offered a support platform providing insurance-navigation help, financial assistance, bridge medicine, and patient-access liaison services for eligible patients.

  Outcome. The program supported access to Catalyst's specialty medicines, particularly in rare-disease treatment settings.

  Source

• 2024Firdapse maximum-dose expansionGeneration change

  Catalyst sought to update the approved dosing range for heavier adult and pediatric LEMS patients.

  What changed. The FDA approved a supplemental application increasing the maximum daily dose for adults and pediatric patients weighing more than 45 kilograms from 80 milligrams to 100 milligrams.

  Aftermath. The approval expanded the labeled dosing flexibility for Firdapse.

  Source
• 2023Acquisition of U.S. FYCOMPA rightsM&A

  Catalyst wanted to broaden its neurological product portfolio with an established epilepsy medicine.

  What changed. The company acquired U.S. rights to FYCOMPA (perampanel).

  Aftermath. FYCOMPA added an epilepsy product to Catalyst's commercial portfolio.

  Source
• 2023Acquisition of North American AGAMREE rightsM&A

  Catalyst sought to expand into Duchenne muscular dystrophy while maintaining a focus on neurological and neuromuscular diseases.

  What changed. Catalyst acquired North American rights to AGAMREE (vamorolone) in July 2023.

  Aftermath. Following FDA approval in October 2023, Catalyst launched AGAMREE commercially in March 2024.

  Source
• 2018Discontinuation of CPP-115 programOther

  Catalyst had licensed CPP-115 and related GABA-inhibitor compounds from Northwestern University in 2009.

  What changed. Catalyst terminated the CPP-115 license and stopped development of the compound.

  Aftermath. The company concentrated more heavily on its rare-disease commercial and regulatory portfolio.

  Source
• 2012Shift toward rare neurological diseasesStrategy

  Catalyst sought a commercially and regulatorily viable focus beyond its earlier addiction-related research programs.

  What changed. The company licensed North American amifampridine phosphate rights from BioMarin for LEMS.

  Aftermath. The transaction became the foundation of Catalyst's commercial-stage rare-disease strategy and led to Firdapse approval.

  Source

• 2019Public controversy over Firdapse pricingControversy

  Firdapse pricing became a public controversy after Senator Bernie Sanders asked Catalyst to explain the cost of the medicine, which had previously been available to some patients through compassionate-use access. Catalyst responded that FDA approval provided broader formal access to the treatment. The issue reflected wider debate about orphan-drug pricing, exclusivity, and affordability.

  Source

• 2024Leadership transition at Catalyst Pharmaceuticals

  Patrick J. McEnany retired as chief executive officer and continued as chairman; Richard J. Daly became chief executive officer on January 1, 2024.

  Leadership change
  Source
• 2024AGAMREE launches for Duchenne muscular dystrophy

  Catalyst commercially launched AGAMREE (vamorolone) oral suspension in March 2024 for patients aged two years and older with Duchenne muscular dystrophy.

  Product launch
  Source
• 2024FDA increases the maximum indicated Firdapse dose

  The FDA approved a supplemental application allowing a higher maximum daily dose of Firdapse for adults and pediatric patients weighing more than 45 kilograms.

  RegulationProduct generation
  Source
• 2023Catalyst acquires U.S. rights to FYCOMPA

  Catalyst acquired U.S. commercial rights to the epilepsy medicine FYCOMPA (perampanel), expanding its neurological portfolio.

  M&AProduct generation
  Source
• 2022Eleventh Circuit upholds Firdapse orphan-drug exclusivity

  In Catalyst Pharmaceuticals, Inc. v. Becerra, the Eleventh Circuit upheld Catalyst's orphan-drug exclusivity and rejected the FDA's interpretation that had permitted approval of a competing product from Jacobus Pharmaceutical.

  LawsuitRegulation
  Source
• 2019Firdapse launches commercially in the United States

  Catalyst began commercial distribution of Firdapse for LEMS in January 2019.

  Product launch
  Source
• 2018FDA approves Firdapse for Lambert-Eaton myasthenic syndrome

  The FDA approved amifampridine under the Firdapse brand for adults with LEMS after Catalyst resubmitted its application following an earlier refusal to accept the filing.

  Product launchRegulation
  Source

1. Catalyst Pharmaceuticals
2. Catalyst Pharmaceuticals official website